Form 4: Puma Biotechnology Director Sells Shares Under 10b5-1 Plan

Brian M. Stuglik, a director at Puma Biotechnology, sold 9,900 shares of common stock at an average price of $3.3867 on June 13, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On June 13, 2024, Brian M. Stuglik, a director of Puma Biotechnology, sold 9,900 shares of the company's common stock.
• The sale was executed at a weighted average price of $3.3867 per share.
• The shares were sold under a pre-arranged 10b5-1(c) trading plan adopted on December 16, 2023.
• Following the transaction, Stuglik directly owns 49,058 shares of Puma Biotechnology.
• The price range for the shares sold was between $3.3001 and $3.5401.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it reports a routine transaction under a pre-arranged trading plan. There is no indication of positive or negative implications for the company's performance.

Industry Context

Sales by company insiders are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The sale of shares by a director could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.

Key Dates